| http://purl.uniprot.org/citations/35933456 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/35933456 | http://www.w3.org/2000/01/rdf-schema#comment | "A significant proportion of breast cancers are driven by ErbB2/Her2 oncoprotein that they overexpress. These malignancies are typically treated with various ErbB2-targeted drugs, but many such cancers develop resistance to these agents and become incurable. Conceivably, treatment of ErbB2-positive cancers could be facilitated by use of agents blocking oncogenic signaling mechanisms downstream of ErbB2. However, current understanding of these mechanisms is limited. The ability of solid tumor cells to resist anoikis, cell death triggered by cell detachment from the extracellular matrix (ECM), is thought to be critical for 3D tumor growth. In an effort to understand the mechanisms of ErbB2-driven breast cancer cell anoikis resistance we found that detachment of non-malignant breast epithelial cells from the ECM upregulates a cell death-promoting tumor suppressor adapter protein BLNK and that ErbB2 blocks this upregulation by reducing tumor cell levels of transcription factor IRF6. We further observed that trastuzumab, a therapeutic anti-ErbB2 antibody, upregulates BLNK in human trastuzumab-sensitive but not trastuzumab-resistant ErbB2-positive breast cancer cells. Moreover, we established that BLNK promotes anoikis by activating p38 MAP kinase and that ErbB2-dependent BLNK downregulation blocks breast cancer cell anoikis. In search for pharmacological approaches allowing to upregulate BLNK in tumor cells we found that clinically approved proteasome inhibitor bortezomib upregulates IRF6 and BLNK in human breast cancer cells and inhibits their 3D growth in a BLNK-dependent manner. In addition, we found that BLNK upregulation in human ErbB2-positive breast cancer cells blocks their ability to form tumors in mice. Furthermore, we used publicly available data on mRNA levels in multiple breast cancers to demonstrate that increased BLNK mRNA levels correlate with increased relapse-free survival in a cohort of approximately 400 patients with ErbB2-positive breast cancer. In summary, we discovered a novel mechanism of ErbB2-driven 3D breast tumor growth mediated by ErbB2-dependent BLNK downregulation."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.org/dc/terms/identifier | "doi:10.1038/s41419-022-05117-9"xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "Francia G."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "Liu X."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "Jiang P."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "Kerbel R.S."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "Tavasoli M."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "Rosen K.V."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "Yoo B.H."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "Mazinani S."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "McPhee M."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/author | "Chipurupalli S."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/date | "2022"xsd:gYear |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/name | "Cell Death Dis"xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/pages | "687"xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/title | "ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth."xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://purl.uniprot.org/core/volume | "13"xsd:string |
| http://purl.uniprot.org/citations/35933456 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/35933456 |
| http://purl.uniprot.org/citations/35933456 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/35933456 |
| http://purl.uniprot.org/uniprot/#_A0A8A0Y2Q6-mappedCitation-35933456 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/35933456 |
| http://purl.uniprot.org/uniprot/#_A0A0R9RWK2-mappedCitation-35933456 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/35933456 |
| http://purl.uniprot.org/uniprot/#_E2I6F8-mappedCitation-35933456 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/35933456 |
| http://purl.uniprot.org/uniprot/#_B3KNL5-mappedCitation-35933456 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/35933456 |
| http://purl.uniprot.org/uniprot/#_B4DTR1-mappedCitation-35933456 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/35933456 |